Earth’s Legal THCa Rick Simpson Oil: OilWell Cannabis of Houston, Texas Delivers 16,590mg 7-Cannabinoid RSO Sublingual Oil with 553mg/mL, 1,500mg THCa Converts to 1,405mg Activated THC for Patient-Controlled Potency, ABC13-Featured Since 2019, Bentley’s 10-Year Miracle Legacy, Baylor-Trained Founder, Lab-Tested COA-Backed, No Medical Card Required, Nationwide & International Shipping

Rick Simpson Oil (RSO) has become one of the most searched cannabis extract terms worldwide, and Earth is no exception. Whether you’re encountering RSO through local dispensaries, online forums, or medical referrals, understanding what this product represents—and how modern formulations have evolved beyond the original recipe—is essential for making informed decisions about your health.

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional. He was a power engineer and maintenance worker—a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, prescribed medications either failed to help or made his condition worse. Cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe it, the request was refused.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 study funded by the National Institute of Health at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s advocacy, though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification or biopsy confirmation has been published in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of a global movement.

Important context: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation or independent medical confirmation means these events cannot be evaluated as scientific proof. They are, however, historically significant as the catalyst for a worldwide cannabis oil movement.

The Crusade—Spreading the Oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community, charging nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era.

This advocacy brought Simpson into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support, he was raided again in 2009, convicted on some charges, and eventually left Canada for Europe, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his personal experience, oil-making process, and broader philosophical views on cannabis, medicine, and institutional suppression. He maintained phoenixtears.ca as his primary online platform for information and advocacy.

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil—particularly high-THC oil made according to his specific method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect financial interests.

Important context: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. The evidence-based assessment of his specific medical claims follows below.

The Traditional RSO Protocol—Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. Here’s the detailed breakdown as Simpson described it:

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake: approximately 30 to 45 milligrams.
• Weeks 2-5: Double the dose approximately every four days to build THC tolerance gradually. By the end of this escalation period, the target is approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5-12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, continuing until the full 60 grams have been consumed.

Administration Methods

• Primary method—oral: Place the dose directly under the tongue (sublingual) or swallow it. Simpson considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method—topical: For skin cancers and external lesions, apply the oil directly to the affected area, cover with a bandage, and change every three to four days. Simpson combined topical application with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method, though he acknowledged inhalation for immediate symptom relief (pain, nausea).

Tolerance and Psychoactive Effects

• Simpson maintained that patients would develop significant tolerance to THC’s psychoactive effects within approximately three to four weeks of consistent dosing.
• He considered euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing.
• He recommended taking initial doses at night or before bed to sleep through the most intense psychoactive effects during early titration.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and inform family members about what to expect.

Post-Protocol Maintenance

After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely. He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.

Dietary and Lifestyle Recommendations

Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition. He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on starting plant material and extraction technique.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the research literature.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

What Is Traditional Rick Simpson Oil—The Product?

Traditional RSO refers to the specific type of concentrated cannabis oil Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials.

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Extraction Solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid or Varsol. He later endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone. Neither naphtha nor isopropyl alcohol is a food-grade solvent, representing a significant safety concern.

Extraction Process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds.
3. The solvent was poured off through a filter (typically cheesecloth) into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material.
5. The combined solvent washes—a dark, cannabinoid-rich liquid—were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa into delta-9 THC, making traditional RSO an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in traditional production.

Terpene Content

Minimal to none. The combination of solvent extraction and high-heat evaporation meant traditional RSO was effectively stripped of its terpene content, despite being derived from a terpene-rich plant.

Standardization and Testing

None. Every batch of traditional RSO was different because it depended entirely on starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual Solvent Risk

This is one of the most significant safety concerns with traditional RSO. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other toxic or carcinogenic compounds. Incomplete solvent purging—very difficult to verify without lab testing—leaves potentially harmful residues in the finished oil. Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s Claims vs. The Evidence Record

Rick Simpson made expansive therapeutic claims about his oil, stating that RSO could cure cancer—including terminal cases—and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows

The preclinical cannabinoid-cancer literature does exist and is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.

What the Preclinical Literature Does Not Show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast and well-documented across all oncology research.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced results that would support cancer-cure claims.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for cancer treatment. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract in consumer vocabulary. These contributions are real and historically significant.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

The Legacy of Rick Simpson and The Evolution of Modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available or performed	Full panel testing for potency, terpenes, pesticides, heavy metals, residual solvents, microbes
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic or carcinogenic compounds. Isopropyl alcohol, while cleaner than naphtha, is also not intended for internal consumption. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to the product-quality discussion in the research literature, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius—was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material—including THCa, CBDa, CBGa, and others—were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes—including myrcene, limonene, and pinene—having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile. The entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it is a description of the environment in which he operated.

The research section of this document takes a fundamentally different approach. It applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of retail and healthcare. Reynosa, meanwhile, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood was marked by exposure to both opportunities and challenges of border life. Early on, he learned to hustle, taking on risky work transporting items across the border for various groups. Those experiences exposed him to complexities and dangers. Many of his best friends have been killed or are in prison because of associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

Bentley’s Story: The Foundation

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD—through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline—and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Colin’s Personal Journey: PTSD and Benzo Withdrawal

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD on an ongoing basis. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Formulas Used by Doctors

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 Media Recognition

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin Valencia and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

From September 2019 to April 2023, five different ABC13 reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

Foundational Philosophy: The 2019 Quote

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote is the seed of everything OilWell would become. The open-source formula publication, the evidence-based research documentation, the refusal to make unsupported claims—it all traces back to this principle.

Current Operations

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced—they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric.

3. Open-source formulas. OilWell publishes their complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace.

4. Evidence-informed, not evidence-overstating. The research section of this document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and The THCa Legal Framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Open-Source Formulas—Why OilWell Publishes Everything

OilWell publishes their complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

The rationale is straightforward: if someone cannot afford OilWell’s products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: they sell a professionally manufactured, lab-tested, standardized product for those who want it, and they publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The Bentley Golden Paste Recipe

The open-source philosophy started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water in a saucepan over low heat, stirring continuously until it forms a thick paste (7-10 minutes). Add more water if it becomes too thick.
2. Add the coconut oil and black pepper. Stir until all ingredients are thoroughly mixed.
3. Allow the paste to cool, then transfer to a jar with a lid. Store in the refrigerator for up to two weeks.
4. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting dosage based on weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe—published for free, years before the RSO formulas were open-sourced—demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company.

The Decarboxylation Choice—Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity—the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3—Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-Free Production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The Broader OilWell Product Portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations—OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two Product Formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Complete RSO Guide—OilWell’s full product guide with science, competitive analysis, protocols, and ordering information.

When to Use Each Format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison—OilWell RSO vs. Alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Texas TCUP Dispensary RSO (e.g., Texas Original)

Dimension	TCUP Dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide and international shipping
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

OilWell RSO vs. Traditional Illegal RSO

This comparison is presented in the Traditional RSO vs. modern formulated RSO table above. Refer to that table for the full eleven-dimension comparison.

Condition-Specific Usage Context

Important disclaimer: The following usage contexts are informed by cannabinoid research and OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Sleep Support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and Global Accessibility

OilWell operates the only same-day RSO delivery system in Houston. Beyond Houston, the company ships nationwide and internationally.

Houston Same-Day Delivery

Zone	Coverage	Delivery fee	Typical turnaround
Texas Medical Center	All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, and more)	FREE	2 to 4 hours
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2 to 4 hours
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (partial), Hobby Airport area	$10	3 to 5 hours
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4 to 6 hours
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20 to $25	Same-day if ordered before 2 PM

Free delivery to the Texas Medical Center—the world’s largest medical complex with over 10 million patient visits annually—reflects OilWell’s commitment to accessibility for the patients who need it most.

Nationwide Shipping

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

International Shipping

OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

The significance of international access cannot be overstated. Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, a chronic pain patient in Australia, or a veteran in the United Kingdom can now potentially access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally—completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

OilWell’s PANDEM1C SEO technology—a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models—drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

How the OilWell Formulas Connect to The Evidence

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the research section of this document. Every terpene in OilWell’s formula—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The research section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. OilWell’s position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand—it is a promise to its customers that it will always strive to deliver the best, most thoughtful cannabis products available. OilWell is not here to follow trends. It is here to set them. And as the company continues to grow, the focus remains on maintaining the same level of integrity, creativity, and commitment that has defined it from the day Bentley got up, walked across the room, and brought his ball to play.

Media Recognition and Community Impact

Colin Valencia—Houston’s Go-To Cannabis Authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving the fourth-largest city in the United States—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

The features document a consistent pattern. When ABC13 needed to explain a new cannabis product to its audience, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

Feature Timeline and Key Moments

September 15, 2019—”Texas CBD businesses booming” (Tom Abrahams)
This earliest feature introduced Colin’s foundational philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021—”Entrepreneur creates direct-to-consumer business” (Tom Abrahams)
This feature established Colin as an ecosystem builder who helped other entrepreneurs like Jonathan Pina. His therapy quote—”pain comes in a lot of different forms”—went deeper into the therapeutic dimension.

May 24, 2021—”What is Delta 8 THC” (Steve Campion)
This investigative feature included Colin’s iconic exchange: “Maybe you want to get high”—radical honesty on mainstream television that became one of his most referenced media moments.

August 20, 2021—”Houston CBD shop giving away free products for COVID vaccine”
This documented OilWell’s largest community health initiative—approximately $35,000 in product (1,000 caviar pre-rolls) donated to encourage COVID-19 vaccination, coordinated with the city of Houston, with no political strings attached.

October 19, 2021—”Texas ban over once legal hemp product Delta 8″ (Shelley Childers)
This captured a defining moment. Just two months after the vaccine giveaway, the legal landscape shifted overnight. Colin had proactively removed all Delta-8 products before enforcement began and warned other operators who were unknowingly shipping Schedule I narcotics.

October 7, 2022—”Biden marijuana pardon—experts weigh in on why Texas won’t see impact” (Nick Natario)
This brought the most personal dimension into public view—the article opened with OilWell’s CBD vending machine innovation, then revealed that Colin has previously faced charges for marijuana possession. That personal history transforms the entire media record.

April 21, 2023—”Marijuana industry getting creative as Texas laws continue to change” (Nick Natario)
Published on 4/20, this completed the four-year arc with Colin’s “Renaissance” framing and coverage of HB1805’s potential to expand medical access in Texas.

The Through-Line—What the Media Record Reveals

Taken together, these seven ABC13 features and one YouTube clip tell a story that no single article could capture on its own.

Consistency across years. Colin appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Through every shift in the cannabis landscape, ABC13 returned to Colin as a primary source.

Breadth of expertise. The features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics.

Community action. The COVID vaccine giveaway and proactive Delta-8 removal are documented evidence of the community-first philosophy. When a public health crisis required action, the company committed real product and coordination with city government. When a regulatory crisis emerged, Colin acted ethically ahead of enforcement and warned others.

Personal stakes. The October 2022 revelation that Colin has a personal marijuana conviction history transforms every feature. Every quote about therapy, education, and not selling snake oil carries additional weight when you understand the person saying it has personally experienced the consequences of cannabis criminalization.

Evolution of language. In 2019, ABC13 called the business “OilWell CBD, a local wholesaler.” By 2021, Colin was an industry authority. By 2023, he was explaining industry dynamics and legal strategy with the confidence of a sector leader. The media record tracks the growth of both the business and its founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, quotable, and accessible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased—it can only be earned.

Research Method and Evidence Weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. Of the compounds listed, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Institutional Baseline from NIH and Related Sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research.
• NCCIH emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.
• Safety concerns repeatedly highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns.
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions.

Cannabinoid Evidence Profiles

CBD

• Evidence profile: strongest human evidence in the current formula set, especially when studied as a purified product.
• Best supported: purified CBD has the most credible human evidence in seizure disorders.
• Anxiety research: a 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but authors stressed that the clinical sample remains limited.
• Pain research: a 2024 systematic review concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence.
• Sleep research: a 2023 insomnia review found that the literature remains methodologically weak.
• Safety concerns: a 2023 systematic review found a real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings.

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG appears pharmacologically distinct from both THC and CBD, with interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, making it mechanistically interesting but not yet clinically established.
• Potential research areas: possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings.
• Bottom line: CBG is a promising minor cannabinoid with limited clinical validation rather than proven therapeutic status.

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.
• Comparative pharmacology: a 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior, but delta-8 appears less potent, likely due to weaker CB1 affinity.
• Public-health literature: a 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials.
• Manufacturing context: commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which raises product-byproduct and lab-testing questions.
• Bottom line: delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa

• Evidence profile: important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What it is: THCa is the acidic precursor of THC and may represent a large share of the THC-related content in raw plant material. It decarboxylates into THC during heating and can also change over time during storage and processing.
• Psychoactivity: THCa itself does not produce psychoactive effects associated with THC, but this distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage.

Delta-9 THC

• Evidence profile: strongest human evidence of the psychoactive cannabinoids, but also the clearest adverse-effect burden.
• Best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes.
• Pain evidence: a 2022 systematic review found that products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation.
• Pharmacokinetics: inhaled THC produces effects within seconds to minutes, peaking roughly within 15 to 30 minutes, tapering over a few hours; oral THC has later onset, later peak, and longer duration.
• Mental-health risk: a 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression.
• Broader safety: includes anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns.

CBN

• Evidence profile: weak human evidence; marketing has clearly moved ahead of the data.
• What it is marketed for: sleep and sedation. That reputation is widespread, but clinical support is far thinner than the market suggests.
• Best review for the sleep claim: a 2021 narrative review screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims.
• Broader sleep literature: a 2024 updated review concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial.
• Chemical context: THC can degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts.
• Bottom line: CBN is one of the clearest examples where cultural reputation is stronger than the current clinical evidence base.

CBC

• Evidence profile: emerging, intriguing, and still overwhelmingly preclinical or review-based.
• Pharmacology and therapeutic interest: a 2024 focused review argues that CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• What the older literature shows: review literature reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.
• Safety caveat: over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.
• Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives.

Terpene Evidence Profiles

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene

• Evidence profile: largely review and preclinical, with useful safety literature.
• Potential activity: a 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature.
• Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature.

Myrcene

• Evidence profile: mostly preclinical, with very limited human evidence.
• Research summary: a 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking.
• Interpretation caution: myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports.

Caryophyllene

• Evidence profile: among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why it stands out: a 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms.
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed, but human clinical confirmation remains limited.

Pinene

• Evidence profile: promising preclinical literature, weak human clinical confirmation.
• Brain-health framing: a 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking.
• Interpretation caution: claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.

Linalool

• Evidence profile: similar to pinene—substantial preclinical interest, limited direct clinical confirmation.
• Research summary: linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials.
• Safety note: as with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.

Humulene

• Evidence profile: translationally interesting, but still early.
• Scoping-review findings: a 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.
• Interpretation caution: those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes.

Terpinolene

• Evidence profile: one of the least clinically characterized terpenes.
• Systematic-review findings: a 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.
• Interpretation caution: even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.

Research Limits and Interpretation

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution.
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products.
• For THCa in particular, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common Overstatements to Avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: the specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

• Overstatement: myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

• Overstatement: terpenes in general have proven entourage effects in patients.
  More accurate: entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.

• Overstatement: delta-8 THC is safe because it is hemp-derived.
  More accurate: delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for The Formulas in This Document

• The most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

RSO Sublingual Oil Formula

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge

Terpene Profile (Both Products)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

Contact Information:
OilWell Cannabis
810 Richmond Avenue, Houston, TX 77006
Phone: (832) 416-2816
Email: [email protected]
Website: https://oilwellcbd.com/
Instagram: @oilwellcbd

Business Hours:
Monday-Thursday: 10:00 AM – 7:00 PM
Friday-Saturday: 10:00 AM – 10:00 PM
Sunday: 10:00 AM – 4:00 PM

Age Requirement: 21+ for all RSO products

Legal Disclaimer: These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider before use. Individual results may vary. Keep out of reach of children. Do not operate vehicles or machinery while using psychoactive cannabinoids. Buyer assumes responsibility for compliance with local laws. Void where prohibited.